

CLAIMS

1. An anti-TRBC1 antigen-binding domain which comprises:
 - (a) a VH domain having an amino acid sequence selected from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; and
 - (b) a VL domain having an amino acid sequence selected from SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.
2. An anti-TRBC1 antigen-binding domain according to Claim 1, which comprises a VH domain having an amino acid sequence of SEQ ID NO: 9 and a VL domain having an amino acid sequence of SEQ ID NO: 19.
3. A chimeric antigen receptor (CAR) which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
4. An antibody which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
5. A bispecific T-cell engager (BiTE) which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
6. An antibody-drug conjugate which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
7. A nucleic acid which encodes a CAR according to Claim 3 or a BiTE according to Claim 5.
8. A nucleic acid construct which comprises a first nucleic acid encoding a CAR according to Claim 3, and a second nucleic acid encoding a suicide gene.
9. A vector comprising a nucleic acid sequence according to Claim 7 or a nucleic acid construct according to Claim 8.
10. A cell comprising a CAR according to Claim 3.

11. A method for making a cell according to Claim 10, which comprises the step of introducing a nucleic acid according to Claim 7 or a vector according to Claim 9 into a cell.

12. A pharmaceutical composition which comprises a plurality of cells according to Claim 10, an antibody according to Claim 4, a BiTE according to Claim 5 or an antibody-drug conjugate according to Claim 7.

13. A pharmaceutical composition according to Claim 12 for use in treating a TRBC1-expressing T-cell lymphoma or leukaemia in a subject.

14. Use of a pharmaceutical composition according to Claim 12 in the manufacture of a medicament for treating a TRBC1-expressing T-cell lymphoma or leukaemia in a subject.

10 15. A pharmaceutical composition for use according to Claim 13 or a use according to Claim 14, in which the TRBC1-expressing T-cell lymphoma or leukaemia is selected from: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); angio-immunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTL), extranodal NK/T-cell
15 lymphoma nasal type, cutaneous T-cell lymphoma, primary cutaneous ALCL, T cell prolymphocytic leukaemia and T-cell acute lymphoblastic leukaemia.

CLAIMS

1. An anti-TRBC1 antigen-binding domain which comprises:
 - (a) a VH domain having an amino acid sequence selected from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18; and
 - (b) a VL domain having an amino acid sequence selected from SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.
2. An anti-TRBC1 antigen-binding domain according to Claim 1, which comprises a VH domain having an amino acid sequence of SEQ ID NO: 9 and a VL domain having an amino acid sequence of SEQ ID NO: 19.
3. A chimeric antigen receptor (CAR) which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
4. An antibody which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
5. A bispecific T-cell engager (BiTE) which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
6. An antibody-drug conjugate which comprises an anti-TRBC1 antigen binding domain according to Claim 1 or 2.
7. A nucleic acid which encodes a CAR according to Claim 3 or a BiTE according to Claim 5.
8. A nucleic acid construct which comprises a first nucleic acid encoding a CAR according to Claim 3; and a second nucleic acid encoding a suicide gene.
9. A vector comprising a nucleic acid sequence according to Claim 7 or a nucleic acid construct according to Claim 8.
10. A cell comprising a CAR according to Claim 3.

11. A method for making a cell according to Claim 10, which comprises the step of introducing a nucleic acid according to Claim 7 or a vector according to Claim 9 into a cell.
12. A pharmaceutical composition which comprises a plurality of cells according to Claim 10, an antibody according to Claim 4, a BiTE according to Claim 5 or an antibody-drug conjugate according to Claim 6.
13. A pharmaceutical composition according to Claim 12 for use in treating a TRBC1-expressing T-cell lymphoma or leukaemia in a subject.
14. Use of a pharmaceutical composition according to Claim 12 in the manufacture of a medicament for treating a TRBC1-expressing T-cell lymphoma or leukaemia in a subject.
15. A pharmaceutical composition for use according to Claim 13 or a use according to Claim 14, in which the TRBC1-expressing T-cell lymphoma or leukaemia is selected from: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); angio-immunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTL), extranodal NK/T-cell lymphoma nasal type, cutaneous T-cell lymphoma, primary cutaneous ALCL, T cell prolymphocytic leukaemia and T-cell acute lymphoblastic leukaemia.